S'abonner

Prostaglandin F2α analogue, bimatoprost ameliorates colistin-induced nephrotoxicity - 11/11/23

Doi : 10.1016/j.biopha.2023.115446 
Lina Joo a, b, 1, Hye Yun Jeong c, 1, Dong Hyuck Bae a, b, Joo Hyun Jee a, b, Woo Hee Choi a, b, d, Hye-Youn Kim e, Sejoong Kim f, g, Dong-Ho Yang c, Heon Yung Gee e, SeongGyeong Jeon a, b, Yun-Gil Roh h, Jongman Yoo a, b, d,
a Department of Microbiology, CHA University School of Medicine, Seongnam, the Republic of Korea 
b CHA Organoid Research Center, CHA University, Seongnam, the Republic of Korea 
c Division of Nephrology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, the Republic of Korea 
d R&D Institute, ORGANOIDSCIENCES LTD., Seongnam, the Republic of Korea 
e Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, the Republic of Korea 
f Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonnggi-do 13620, the Republic of Korea 
g Department of Internal Medicine, Seoul National University College of Medicine Seoul, 03080, the Republic of Korea 
h Program in Health Policy, Chung-Buk National University, Republic of Korea 

Corresponding author at: Department of Microbiology, CHA University School of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam-si, 13496, the Republic of Korea.Department of Microbiology, CHA University School of Medicine59 Yatap-ro, Bundang-guSeongnam-si13496the Republic of Korea

Abstract

Colistin (polymyxin E) is an antibiotic that is effective against multidrug-resistant gram-negative bacteria. However, the high incidence of nephrotoxicity caused by colistin limits its clinical use. To identify compounds that might ameliorate colistin-induced nephrotoxicity, we obtained 1707 compounds from the Korea Chemical Bank and used a high-content screening (HCS) imaging-based assay. In this way, we found that bimatoprost (one of prostaglandin F2α analogue) ameliorated colistin-induced nephrotoxicity. To further assess the effects of bimatoprost on colistin-induced nephrotoxicity, we used in vitro and in vivo models. In cultured human proximal tubular cells (HK-2), colistin induced dose-dependent cytotoxicity. The number of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive cells, indicative of apoptosis, was higher in colistin-treated cells, but this effect of colistin was ameliorated by cotreatment with bimatoprost. The generation of reactive oxygen species, assessed using 2,7-dichlorodihydrofluorescein diacetate, was less marked in cells treated with both colistin and bimatoprost than in those treated with colistin alone. Female C57BL/6 mice (n = 10 per group) that were intraperitoneally injected with colistin (10 mg/kg/12 hr) for 14 days showed high blood urea nitrogen and serum creatinine concentrations that were reduced by the coadministration of bimatoprost (0.5 mg/kg/12 hr). In addition, kidney injury molecule-1 (KIM1) and Neutrophil gelatinase-associated lipocalin (NGAL) expression also reduced by bimatoprost administration. Further investigation in tubuloid and kidney organoids also showed that bimatoprost attenuated the nephrotoxicity by colistin, showing dose-dependent reducing effect of KIM1 expression. In this study, we have identified bimatoprost, prostaglandin F2α analogue as a drug that ameliorates colistin-induced nephrotoxicity.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

Colistin treats multidrug-resistant bacterial infections, but its nephrotoxicity risk limits use.
High-Content Screening reveals Bimatoprost as a potential protector against colistin's nephrotoxicity.
Bimatoprost might be a protective drug for nephrotoxicity, its systemic use needs more study.

Le texte complet de cet article est disponible en PDF.

Abbreviations : MDR, PGE2, HCS, HK-2, TUNEL, DCF-DA, LTL, KIM1, NGAL, ROS, PH, E-cad

Keywords : Bimatoprost, Colistin, Nephrotoxicity, Drug repurposing, Oxidative stress, Apoptosis


Plan


© 2023  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 168

Article 115446- décembre 2023 Retour au numéro
Article précédent Article précédent
  • Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling
  • Arezou Azizsoltani, Behzad Hatami, Mohammad Reza Zali, Vahideh Mahdavi, Kaveh Baghaei, Effat Alizadeh
| Article suivant Article suivant
  • Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin
  • David Zaragoza-Huesca, Maria Carmen Rodenas, Julia Peñas-Martínez, Irene Pardo-Sánchez, Jorge Peña-García, Salvador Espín, Guillermo Ricote, Andrés Nieto, Francisco García-Molina, Vicente Vicente, Maria Luisa Lozano, Alberto Carmona-Bayonas, Victoriano Mulero, Horacio Pérez-Sánchez, Irene Martínez-Martínez

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.